Nechanitzky, Robert
Nechanitzky, Duygu
Ramachandran, Parameswaran
Duncan, Gordon S.
Zheng, Chunxing
Göbl, Christoph
Gill, Kyle T.
Haight, Jillian
Wakeham, Andrew C.
Snow, Bryan E.
Bradaschia-Correa, Vivian
Ganguly, Milan
Lu, Zhibin http://orcid.org/0000-0001-6281-1413
Saunders, Mary E.
Flavell, Richard A. http://orcid.org/0000-0003-4461-0778
Mak, Tak W. http://orcid.org/0000-0001-6766-861X
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
European Molecular Biology Organization (ALTF 725-2015, ALTF 725-2015)
Article History
Received: 7 January 2022
Revised: 3 November 2022
Accepted: 11 November 2022
First Online: 17 December 2022
Competing interests
: The authors do not have competing financial interests concerning the work described. T. Mak owns equity in Treadwell Therapeutics Inc. and Agios Pharmaceuticals and is a consultant for AstraZeneca and Tessa Therapeutics.
: The Ontario Cancer Institute Animal Care Committee approved all animal research and mouse experiments.